CN101062009A - 含肉毒神经毒素的治疗剂 - Google Patents
含肉毒神经毒素的治疗剂 Download PDFInfo
- Publication number
- CN101062009A CN101062009A CNA2007101102394A CN200710110239A CN101062009A CN 101062009 A CN101062009 A CN 101062009A CN A2007101102394 A CNA2007101102394 A CN A2007101102394A CN 200710110239 A CN200710110239 A CN 200710110239A CN 101062009 A CN101062009 A CN 101062009A
- Authority
- CN
- China
- Prior art keywords
- neurotoxin
- complex
- type
- botulinum
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 23
- 231100001103 botulinum neurotoxin Toxicity 0.000 title claims abstract description 16
- 239000002581 neurotoxin Substances 0.000 claims abstract description 64
- 231100000618 neurotoxin Toxicity 0.000 claims abstract description 64
- 101710138657 Neurotoxin Proteins 0.000 claims abstract description 52
- 241000193155 Clostridium botulinum Species 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 14
- 208000005392 Spasm Diseases 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 230000003472 neutralizing effect Effects 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 6
- 208000014094 Dystonic disease Diseases 0.000 claims description 5
- 208000010118 dystonia Diseases 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 206010044074 Torticollis Diseases 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000037303 wrinkles Effects 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 206010005159 blepharospasm Diseases 0.000 claims description 3
- 230000000744 blepharospasm Effects 0.000 claims description 3
- 208000018197 inherited torticollis Diseases 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 206010029410 night sweats Diseases 0.000 claims description 3
- 230000036565 night sweats Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 206010040954 Skin wrinkling Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 12
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 8
- 230000000536 complexating effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 description 17
- 231100000765 toxin Toxicity 0.000 description 17
- 108700012359 toxins Proteins 0.000 description 17
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 16
- 229940089093 botox Drugs 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000004448 titration Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 7
- 229940098753 dysport Drugs 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 101710186708 Agglutinin Proteins 0.000 description 6
- 101710146024 Horcolin Proteins 0.000 description 6
- 101710189395 Lectin Proteins 0.000 description 6
- 101710179758 Mannose-specific lectin Proteins 0.000 description 6
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 6
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 6
- 239000000910 agglutinin Substances 0.000 description 6
- 229940053031 botulinum toxin Drugs 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229940094657 botulinum toxin type a Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 101000761717 Hydrophis lapemoides Short neurotoxin 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101710106950 Long neurotoxin 2 Proteins 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 101000800747 Ophiophagus hannah Long neurotoxin 1 Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000295650 Plagiobothrys arizonicus Species 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002546 agglutinic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000632 dystonic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000005111 flow chemistry technique Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- LWYXLXAMDLNBFQ-UHFFFAOYSA-N iso-6-Carnavalin Natural products CC(O)CCCCCCCCCCC1CCC(O)C(C)N1 LWYXLXAMDLNBFQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19925739.6 | 1999-06-07 | ||
| DE19925739A DE19925739A1 (de) | 1999-06-07 | 1999-06-07 | Therapeutikum mit einem Botulinum-Neurotoxin |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB008086419A Division CN100389820C (zh) | 1999-06-07 | 2000-05-26 | 含肉毒神经毒素的治疗剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101062009A true CN101062009A (zh) | 2007-10-31 |
Family
ID=7910318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB008086419A Expired - Fee Related CN100389820C (zh) | 1999-06-07 | 2000-05-26 | 含肉毒神经毒素的治疗剂 |
| CNA2007101102394A Pending CN101062009A (zh) | 1999-06-07 | 2000-05-26 | 含肉毒神经毒素的治疗剂 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB008086419A Expired - Fee Related CN100389820C (zh) | 1999-06-07 | 2000-05-26 | 含肉毒神经毒素的治疗剂 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US7964199B1 (enExample) |
| EP (1) | EP1185291B2 (enExample) |
| JP (2) | JP2003505343A (enExample) |
| KR (1) | KR100466407B1 (enExample) |
| CN (2) | CN100389820C (enExample) |
| AR (1) | AR024306A1 (enExample) |
| AT (1) | ATE258803T1 (enExample) |
| AU (1) | AU774590B2 (enExample) |
| CA (1) | CA2376193C (enExample) |
| CO (1) | CO5170431A1 (enExample) |
| CZ (1) | CZ20014351A3 (enExample) |
| DE (3) | DE19925739A1 (enExample) |
| DK (1) | DK1185291T3 (enExample) |
| EA (1) | EA004202B1 (enExample) |
| ES (1) | ES2215056T5 (enExample) |
| GE (1) | GEP20043200B (enExample) |
| HU (1) | HUP0201530A3 (enExample) |
| IL (2) | IL146974A0 (enExample) |
| MX (1) | MXPA01012540A (enExample) |
| NO (1) | NO20015964L (enExample) |
| PL (1) | PL198958B1 (enExample) |
| PT (1) | PT1185291E (enExample) |
| TW (1) | TWI251492B (enExample) |
| UA (1) | UA72253C2 (enExample) |
| WO (1) | WO2000074703A2 (enExample) |
| ZA (1) | ZA200110074B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103501802A (zh) * | 2011-06-27 | 2014-01-08 | 金相德 | 皮肤疤痕治疗用药物组合物及利用其的皮肤疤痕治疗方法 |
| CN108350043A (zh) * | 2015-11-30 | 2018-07-31 | 株式会社大熊 | 用于产生肉毒杆菌毒素的方法 |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
| US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US6821520B2 (en) | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
| JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
| US7140371B2 (en) | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
| US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
| JPWO2003082315A1 (ja) * | 2002-03-29 | 2005-07-28 | 財団法人化学及血清療法研究所 | 筋緊張亢進疾患治療剤 |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| EP1545207B1 (en) * | 2002-08-19 | 2018-03-14 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
| US7824693B2 (en) | 2002-08-19 | 2010-11-02 | Ira Sanders | Treatment of fine wrinkles with clostridia neurotoxins |
| US20120114697A1 (en) | 2002-08-19 | 2012-05-10 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
| US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| MXPA05009425A (es) * | 2003-03-06 | 2006-02-10 | Botulinum Toxin Res Ass Inc | Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica. |
| US6838434B2 (en) * | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
| US20060153877A1 (en) * | 2003-06-20 | 2006-07-13 | Shunji Kozaki | Remedies for dissease with hypermyotonia |
| US7354740B2 (en) * | 2003-09-25 | 2008-04-08 | Allergan, Inc. | Animal product free system and process for purifying a botulinum toxin |
| US6974579B2 (en) * | 2004-01-08 | 2005-12-13 | Allergan, Inc. | Methods for treating vascular disorders |
| PT2985039T (pt) | 2004-03-03 | 2018-11-09 | Revance Therapeutics Inc | Aplicação tópica e administração transdérmica de toxinas botulínicas |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US8092788B2 (en) | 2004-03-03 | 2012-01-10 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| BRPI0513850A (pt) | 2004-07-26 | 2008-05-20 | Merz Pharma Gmbh & Co Kgaa | composição terapêutica com uma neurotoxina botulìnica |
| US7179474B2 (en) | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
| US7429386B2 (en) | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
| CN101027083A (zh) * | 2004-09-27 | 2007-08-29 | 莫茨药物股份两合公司 | 梭状芽孢杆菌神经毒素在组织愈合中的用途 |
| SG160357A1 (en) | 2005-03-03 | 2010-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US7419675B2 (en) | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
| ES2326916T3 (es) * | 2005-06-17 | 2009-10-21 | MERZ PHARMA GMBH & CO. KGAA | Aparato y metodo para la produccion de compuestos biologicamente activos por fermentacion. |
| NZ568216A (en) | 2005-11-17 | 2012-09-28 | Revance Therapeutics Inc | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
| AR061669A1 (es) | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
| EP2048156A1 (en) * | 2007-10-12 | 2009-04-15 | Merz Pharma GmbH & Co.KGaA | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin |
| JP2010528999A (ja) * | 2007-06-01 | 2010-08-26 | メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー | ボツリヌストキシンの神経毒成分に基づいた、温度安定な筋弛緩薬を固体形態で供給する方法 |
| DE102007038015A1 (de) * | 2007-08-10 | 2009-02-19 | Hefter, Harald, Prof. Dr. med. Dr. rer. nat. | Verwendung eines Neurotoxins |
| US9161970B2 (en) * | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
| EP2072057A1 (en) | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury |
| EP2072039A1 (en) * | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects |
| US8540987B2 (en) * | 2008-01-29 | 2013-09-24 | Institute For Antibodies Co., Ltd. | Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody |
| US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| AU2009223161B2 (en) * | 2008-03-14 | 2014-10-30 | Allergan, Inc. | Immuno-based botulinum toxin serotype A activity assays |
| US20110033431A1 (en) * | 2008-03-31 | 2011-02-10 | The Chemo-Sero-Therapeutic Research Institute | Type a2 botulinum toxin preparation |
| BRPI0916964A2 (pt) | 2008-08-29 | 2015-11-24 | Merz Pharma Gmbh & Co Kgaa | polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo |
| ES2426667T3 (es) | 2008-09-09 | 2013-10-24 | Susanne Grafe | Toxina botulínica para introducir infertilidad temporal en un vertebrado (por ejemplo, un ser humano) |
| CN101386648B (zh) * | 2008-09-25 | 2012-05-30 | 中国人民解放军军事医学科学院微生物流行病研究所 | 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途 |
| WO2010096134A1 (en) | 2008-12-04 | 2010-08-26 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
| EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| JP2011074025A (ja) * | 2009-09-30 | 2011-04-14 | Chemo-Sero-Therapeutic Research Inst | ボツリヌス毒素の精製方法 |
| HRP20181869T1 (hr) | 2009-10-21 | 2019-01-11 | Revance Therapeutics, Inc. | Metode i sustavi za pročišćavanje nekompleksiranog botulinskog neurotoksina |
| KR101134146B1 (ko) * | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| WO2012048854A2 (en) | 2010-10-12 | 2012-04-19 | Merz Pharma Gmbh & Co. Kgaa | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
| US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
| JP6517800B2 (ja) * | 2013-07-30 | 2019-05-22 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン | ボツリヌス毒素の高純度神経毒成分の製造方法とその使用 |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| EP3285800B1 (en) * | 2015-04-24 | 2019-09-18 | Consiglio Nazionale Delle Ricerche | A new therapeutic use of the botulinum neurotoxin serotype a |
| HUE046449T2 (hu) | 2016-09-13 | 2020-03-30 | Allergan Inc | Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények |
| KR102463881B1 (ko) * | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
| WO2018175688A1 (en) * | 2017-03-22 | 2018-09-27 | Bonti, Inc. | Botulinum neurotoxins for use in therapy |
| KR20190126794A (ko) | 2017-03-24 | 2019-11-12 | 메르츠 파마 게엠베하 운트 코. 카가아 | 타액과다증의 치료에서의 보툴리늄 신경독소의 개선된 용도 |
| WO2020047159A1 (en) | 2018-08-28 | 2020-03-05 | Ira Sanders | Skin therapeutics |
| US20210393748A1 (en) | 2018-10-02 | 2021-12-23 | Merz Pharma Gmbh & Co. Kgaa | Novel uses of botulinum neurotoxin for treating lipoedema |
| SG11202107565RA (en) | 2019-02-21 | 2021-08-30 | Merz Pharma Gmbh & Co Kgaa | Novel uses of botulinum neurotoxin for the treatment of tremor |
| TW202214211A (zh) | 2020-06-05 | 2022-04-16 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素用於治療臉部皺紋的用途及治療臉部皺紋的方法 |
| KR102724651B1 (ko) * | 2021-07-08 | 2024-11-01 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
| TW202400122A (zh) | 2022-02-28 | 2024-01-01 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素用於降低皮膚毛孔尺寸及／或皮脂產生之用途、以及降低皮膚毛孔尺寸及／或皮脂產生的方法 |
| AU2023400493A1 (en) | 2022-11-28 | 2025-04-10 | Merz Pharma Gmbh & Co. Kgaa | High concentration botulinum toxin treatment for neck rejuvenation |
| TW202435908A (zh) | 2022-11-28 | 2024-09-16 | 德商梅茲製藥有限兩合公司 | 組成物及應用其之注射裝置 |
| WO2024194181A1 (en) | 2023-03-20 | 2024-09-26 | Merz Therapeutics GmbH | Nh3 scavenger for use in the treatment of mobility disability in a post-stroke patient |
| WO2024240868A1 (en) | 2023-05-23 | 2024-11-28 | Merz Therapeutics GmbH | Botulinum toxin for treating peripheral neuropathic pain |
| WO2025012403A1 (en) | 2023-07-12 | 2025-01-16 | Merz Pharma Gmbh & Co. Kgaa | Treatment of hyperpigmentation conditions by botulinum toxin |
| WO2025228877A1 (en) | 2024-04-29 | 2025-11-06 | Merz Therapeutics GmbH | Botulinum toxin for the preventive treatment of migraine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09500869A (ja) | 1993-05-14 | 1997-01-28 | エス． アーノン，スティーブン | トキシンの治療的使用に対する副作用および非感受性を防ぐ方法 |
| JP4249802B2 (ja) | 1993-06-10 | 2009-04-08 | アラーガン、インコーポレイテッド | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ |
| DE69434443T2 (de) | 1993-12-28 | 2006-05-24 | Allergan, Inc., Irvine | Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung |
| US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| DK0758900T3 (da) | 1994-05-09 | 2002-07-29 | William J Binder | Botulinumtoksin til reduktion af migræne-hovedpinesmerter |
| AU2907695A (en) | 1994-08-08 | 1996-03-07 | Wisconsin Alumni Research Foundation | Purification and pharmaceutical compositions containing type g botulinum neurotoxin |
| US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| AU6034396A (en) * | 1995-06-06 | 1996-12-24 | L. Bruce Pearce | Improved compositions and methods for chemodenervation using neurotoxins |
| US5939070A (en) * | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
| ATE314085T1 (de) * | 1997-07-15 | 2006-01-15 | Univ Colorado | Verwendung von botulinumtoxin zur behandlung von harninkontinenz |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| DE19856897A1 (de) * | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
| DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US6358917B1 (en) * | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
| US6787517B1 (en) * | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
| DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| KR101818895B1 (ko) * | 2009-07-02 | 2018-01-15 | 메르츠 파마 게엠베하 운트 코. 카가아 | 생물학적 활성이 감소된 신경독 |
-
1999
- 1999-06-07 DE DE19925739A patent/DE19925739A1/de not_active Withdrawn
-
2000
- 2000-05-26 AT AT00943666T patent/ATE258803T1/de active
- 2000-05-26 ES ES00943666T patent/ES2215056T5/es not_active Expired - Lifetime
- 2000-05-26 CN CNB008086419A patent/CN100389820C/zh not_active Expired - Fee Related
- 2000-05-26 JP JP2001501237A patent/JP2003505343A/ja active Pending
- 2000-05-26 DE DE10081516T patent/DE10081516D2/de not_active Ceased
- 2000-05-26 GE GEAP20006278A patent/GEP20043200B/en unknown
- 2000-05-26 CA CA002376193A patent/CA2376193C/en not_active Expired - Fee Related
- 2000-05-26 KR KR10-2001-7015668A patent/KR100466407B1/ko not_active Expired - Fee Related
- 2000-05-26 AU AU58047/00A patent/AU774590B2/en not_active Ceased
- 2000-05-26 UA UA2002010181A patent/UA72253C2/uk unknown
- 2000-05-26 EA EA200200017A patent/EA004202B1/ru not_active IP Right Cessation
- 2000-05-26 HU HU0201530A patent/HUP0201530A3/hu unknown
- 2000-05-26 MX MXPA01012540A patent/MXPA01012540A/es active IP Right Grant
- 2000-05-26 WO PCT/DE2000/001777 patent/WO2000074703A2/de not_active Ceased
- 2000-05-26 CZ CZ20014351A patent/CZ20014351A3/cs unknown
- 2000-05-26 CN CNA2007101102394A patent/CN101062009A/zh active Pending
- 2000-05-26 PT PT00943666T patent/PT1185291E/pt unknown
- 2000-05-26 IL IL14697400A patent/IL146974A0/xx active IP Right Grant
- 2000-05-26 EP EP00943666A patent/EP1185291B2/de not_active Expired - Lifetime
- 2000-05-26 DK DK00943666T patent/DK1185291T3/da active
- 2000-05-26 US US10/018,373 patent/US7964199B1/en not_active Expired - Lifetime
- 2000-05-26 DE DE50005208T patent/DE50005208D1/de not_active Expired - Lifetime
- 2000-05-26 PL PL352468A patent/PL198958B1/pl not_active IP Right Cessation
- 2000-06-07 AR ARP000102818A patent/AR024306A1/es unknown
- 2000-06-07 CO CO00042309A patent/CO5170431A1/es not_active Application Discontinuation
- 2000-08-24 TW TW089111212A patent/TWI251492B/zh not_active IP Right Cessation
-
2001
- 2001-12-06 IL IL146974A patent/IL146974A/en not_active IP Right Cessation
- 2001-12-06 ZA ZA200110074A patent/ZA200110074B/xx unknown
- 2001-12-06 NO NO20015964A patent/NO20015964L/no unknown
-
2007
- 2007-05-16 JP JP2007130686A patent/JP2007238627A/ja not_active Withdrawn
-
2011
- 2011-05-11 US US13/068,439 patent/US20110217287A1/en not_active Abandoned
- 2011-11-23 US US13/303,973 patent/US8398998B2/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103501802A (zh) * | 2011-06-27 | 2014-01-08 | 金相德 | 皮肤疤痕治疗用药物组合物及利用其的皮肤疤痕治疗方法 |
| CN108350043A (zh) * | 2015-11-30 | 2018-07-31 | 株式会社大熊 | 用于产生肉毒杆菌毒素的方法 |
| CN108350043B (zh) * | 2015-11-30 | 2022-06-14 | 株式会社大熊 | 用于产生肉毒杆菌毒素的方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101062009A (zh) | 含肉毒神经毒素的治疗剂 | |
| EP0889730B1 (en) | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation | |
| EP1005867B2 (en) | Botulinum toxins for modulating cholinergic controlled secretions | |
| EP0654040A1 (en) | Pharmaceutical composition containing botulinum b complex | |
| EP3932938A1 (en) | Botulinum toxin type a complex, and formulation thereof and usage method therefor | |
| WO2008050866A1 (fr) | Préparation contenant une toxine botulinique de type a hautement purifiée issue d'un pathogène du botulisme chez l'enfant | |
| EP1491205A1 (en) | Remedy for hypermyotonia | |
| HK1110204A (en) | Therapeutic agent comprising a botulinum neurotoxin | |
| HK40085605A (en) | Botulinum toxin type a complex, and formulation thereof and usage method therefor | |
| HK1047403B (en) | Therapeutic agent comprising a botulinum neurotoxin | |
| HK40063817A (en) | Botulinum toxin type a complex, and formulation thereof and usage method therefor | |
| COLVILLE | THE INTERACTION OF TETANUS TOXIN | |
| DE20023785U1 (de) | Therapeutikum mit einem Botulinum-Neurotoxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1110204 Country of ref document: HK |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20071031 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1110204 Country of ref document: HK |